[{"NetIncomeLoss_2_Q2_USD":-115011000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":67675000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":68164000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":37150000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-13000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q2_USD":974470000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":7718000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1993802.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":49000.0,"AssetsCurrent_0_Q2_USD":549404000.0,"MarketableSecuritiesRealizedGainLoss_2_Q2_USD":0.0,"ContractWithCustomerLiability_0_Q2_USD":62752000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":16683000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":7761000.0,"CommonStockSharesIssued_0_Q2_shares":68331780.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":421402000.0,"Assets_0_Q2_USD":672243000.0,"ShareBasedCompensation_2_Q2_USD":17038000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":77070000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_Q2_USD":27.85,"ProceedsFromIssuanceOfCommonStock_25_Q2_USD":1166100000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":38.7,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":48.44,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":8703000.0,"CommonStockSharesAuthorized_0_Q2_shares":120000000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":6163000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":30277000.0,"MarketableSecuritiesCurrent_0_Q2_USD":399140000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":62.82,"ResearchAndDevelopmentExpense_2_Q2_USD":98160000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":58884000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":27.75,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_Q2_shares":353072.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":10135000.0,"ProceedsFromStockPlans_2_Q2_USD":970000.0,"AccountsReceivableNetCurrent_0_Q2_USD":1993000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_Q2_pure":0.722,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q2_pure":0.73,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0_Q2_USD":51.33,"CommonStockValue_0_Q2_USD":7000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":3225000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":65728000.0,"CostsAndExpenses_2_Q2_USD":128437000.0,"CostsAndExpenses_1_Q2_USD":75567000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":198499000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-115025000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-68807000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-2606000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_Q2_pure":0.009,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q2_pure":0.011,"OtherAssetsNoncurrent_0_Q2_USD":4977000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":129879000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":63259000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1044939000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0_Q2_shares":497185.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":15.05,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":12995000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-11179000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":6550000.0,"OperatingIncomeLoss_1_Q2_USD":-69017000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-137000.0,"CommonStockSharesOutstanding_0_Q2_shares":68331780.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":185431000.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":11179000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-1000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":37000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":10614000.0,"MarketableSecuritiesUnrealizedGainLoss_2_Q2_USD":-14000.0,"MarketableSecuritiesUnrealizedGainLoss_1_Q2_USD":-1000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-105357000.0,"MarketableSecuritiesNoncurrent_0_Q2_USD":22262000.0,"LiabilitiesCurrent_0_Q2_USD":73963000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-31911000.0,"AccountsPayableCurrent_0_Q2_USD":6854000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":19503000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":4603000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":229000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":132695000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_Q2_shares":26235.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":1409370.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":970000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":1969000.0,"ProceedsFromIssuanceOfConvertiblePreferredStock_25_Q2_USD":85000000.0,"RestrictedCashEquivalents_0_Q2_USD":2816000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":18530000.0,"NetIncomeLoss_1_Q2_USD":-68806000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":18392000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-550120000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":2815568.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":7263658.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q2_USD":208000.0,"ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_2_Q2_USD":-11179000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_Q2_USD":84500000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1_Q2_USD":29700000.0,"InvestmentIncomeInterest_2_Q2_USD":431000.0,"InvestmentIncomeInterest_1_Q2_USD":211000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q2_pure":0.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":22544000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":61.07,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":13.84,"LiabilitiesAndStockholdersEquity_0_Q2_USD":672243000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":10039000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":17038000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":10614000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":91600000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_Q2_shares":298214.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":7415000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0_Q2_USD":22800000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.7,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.01,"ProfitLoss_2_Q2_USD":-115011000.0,"StockholdersEquity_0_Q2_USD":494813000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":40208000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":5350000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":421414000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-2868000.0,"OperatingIncomeLoss_2_Q2_USD":-115442000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":4109000.0,"Ticker":"NTLA","CIK":"1652130","name":"INTELLIA THERAPEUTICS, INC.","OfficialName":"Intellia Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"4259315236.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]